GLP-1 Medications Compared: Ozempic vs Wegovy vs Mounjaro vs Zepbound

All the medications discussed here work on the GLP-1 receptor system, but they fall into two categories:

Semaglutide (Ozempic, Wegovy) is a pure GLP-1 receptor agonist. It mimics the natural GLP-1 hormone, targeting one specific pathway. It was the first to demonstrate dramatic effects on both weight loss and food noise reduction.

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. It targets two hormone pathways simultaneously — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual action may explain why some patients find it more effective.

While no head-to-head clinical trials have specifically measured “food noise” as an endpoint, patient-reported experiences and emerging research suggest some patterns:

Semaglutideprovides significant food noise reduction for most patients. The effect is typically described as gradual — a slow turning-down of the volume over weeks. Many patients first notice it when they realize they've gone a few hours without thinking about food.

Tirzepatide is frequently reported as providing more dramatic food noise reduction. Patients more commonly describe a sudden, distinct moment when the noise stops. The dual mechanism targeting both GIP and GLP-1 receptors may create a more comprehensive effect on appetite and reward signaling.

Both medications are effective, and individual responses vary significantly. Some patients respond better to semaglutide, others to tirzepatide. If one doesn't provide adequate food noise reduction, switching to the other is a reasonable conversation to have with your healthcare provider.

Both medication classes share similar gastrointestinal side effects, though the profile differs slightly:

Nausea is the most common side effect for both, typically worst during dose escalation. It tends to be more common with semaglutide but generally improves over time with both medications.

Constipation is more commonly reported with semaglutide, while diarrhea is more common with tirzepatide. Both are usually manageable with proper nutritional strategies and improve as the body adjusts.

Serious side effects are rare for both classes but can include pancreatitis, gallbladder disease, and thyroid concerns (semaglutide carries a black box warning for medullary thyroid carcinoma based on animal studies). All patients should be monitored by their healthcare provider.

Without insurance, all four medications are expensive — typically $900-$1,300 per month at list price. Insurance coverage varies widely:

Diabetes-approved medications (Ozempic, Mounjaro) are more likely to be covered by insurance for patients with type 2 diabetes. Off-label use for weight management is often not covered.

Weight-management-approved medications (Wegovy, Zepbound) may be covered by plans that include obesity treatment, but many insurance plans still exclude weight loss medications. Coverage is expanding as more evidence supports these treatments.

Manufacturer savings programs, compounding pharmacies, and patient assistance programs can help reduce costs. Your healthcare provider's office may be able to help navigate insurance and access issues.

The GLP-1 field is evolving rapidly. Oral formulations of semaglutide (Rybelsus for diabetes, with a weight-management version in development) could eliminate the need for injections. Triple agonists targeting GLP-1, GIP, and glucagon receptors simultaneously are in clinical trials, showing even greater efficacy. Longer-acting formulations that require less frequent dosing are also being developed.

As the science advances, people experiencing food noise will have more options than ever for finding relief.